Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Phase 2
52
about 4.1 years
18+
1 site in SC
What this study is about
Researchers are testing whether NALIRIFOX or a modified treatment (mGAP) is more effective than standard chemotherapy for people with locally advanced or metastatic pancreatic cancer. The trial will last about 1484 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 5-Fluorouracil
- 2.Take Cisplatin
- 3.Take Gemcitabine (mg/m²)
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), gemcitabine, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), paclitaxel (Taxane chemotherapy; stabilizes microtubules), oxaliplatin
injection, intravenous, injection (Injection), infusion
Primary: Overall response rate (ORR) assessed by imaging.
Secondary: Best overall response (BOR) assessed by imaging., Disease control rate (DCR)., Duration of response (DOR)., Overall survival (OS)., Progression-free survival (PFS)., Toxicity profile of each chemotherapy regimen.